Observational studyBritish journal of haematology2019
Effect of renin-angiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease.
Observational study in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07175051 (Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.Blood advances · 2019Guideline
- Blockade of the mineralocorticoid receptor improves markers of human endothelial cell dysfunction and hematological indices in a mouse model of sickle cell disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Trial
- The Unfinished Story of Sickle Cell Nephropathy: A Narrative Review of Knowledge Gaps and Research Imperatives.Journal of clinical medicine · 2026Review
- Renin-angiotensin-aldosterone system inhibition exacerbates anemia in sickle cell disease.Blood · 2026Article
- Natural History of Chronic Kidney Disease in Sickle Cell Disease.American journal of hematology · 2026Review
- Kidney Function Decline in Sickle Cell Disease: Associations with Renin-Angiotensin System Inhibitors.Kidney360 · 2026Observational
- Management of Kidney Disease with Sickle Cell Disease.Journal of the American Society of Nephrology : JASN · 2025Review
- Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis.Blood advances · 2022Article
- The nephropathy of sickle cell trait and sickle cell disease.Nature reviews. Nephrology · 2022Review
- Article
- Longitudinal study of glomerular hyperfiltration and normalization of estimated glomerular filtration in adults with sickle cell disease.British journal of haematology · 2021Article
- Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.British journal of pharmacology · 2021Article
- Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis.Haematologica · 2021Article
- Optimal disease management and health monitoring in adults with sickle cell disease.Hematology. American Society of Hematology. Education Program · 2019Review
- Rapid decline in estimated glomerular filtration rate is common in adults with sickle cell disease and associated with increased mortality.British journal of haematology · 2019Article
- Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019Observational
- Levels of angiotensin-converting enzyme 1 and 2 in serum and urine of children with Sickle Cell Disease.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Although renin-angiotensin-aldosterone system (RAAS) blocking agents decrease albuminuria in short-term studies, there is no evidence confirming their long-term efficacy in sickle cell disease (SCD). In a single-centre, retrospective study, we evaluated the long-term effect of RAAS blocking agents on proteinuria and declining estimated glomerular filtration rates (eGFR). Eighty-six patients on RAAS blocking agents for proteinuria, followed for a median of 2·28 years, were compared with 68 patients with proteinuria followed for 2·24 years who were not receiving such treatment. The log odds of proteinuria decreased over time in patients on RAAS blocking agents (β: -0·23, P = 0·03) and in the non-treatment group (β: -0·54, P < 0·0001), but was not statistically different between both groups (β: 0·31, P = 0·063). The eGFR declined over time in patients on RAAS blocking agents (β: -2·78, P < 0·0001) and in those not on such treatment (β: -4·7, P < 0·0001), and was statistically different between both groups (β: 1·9, P = 0·0002). Baseline eGFR was associated with mortality (Hazard rato: 0·97, P < 0·0001), but RAAS blocking agents had no significant effect on mortality. These data suggest that RAAS blockade may slow the loss of kidney function in SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.